- Home
- RDI vs FGEN Comparison
RDI vs FGEN Comparison
Compare RDI & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- FGEN
- Stock Information
- Founded
- RDI 1937
- FGEN 1993
- Country
- RDI United States
- FGEN United States
- Employees
- RDI N/A
- FGEN N/A
- Industry
- RDI Movies/Entertainment
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- FGEN Health Care
- Exchange
- RDI Nasdaq
- FGEN Nasdaq
- Market Cap
- RDI 30.6M
- FGEN 33.5M
- IPO Year
- RDI N/A
- FGEN 2014
- Fundamental
- Price
- RDI $1.27
- FGEN $5.63
- Analyst Decision
- RDI Hold
- FGEN Strong Buy
- Analyst Count
- RDI 1
- FGEN 1
- Target Price
- RDI $2.40
- FGEN $250.00
- AVG Volume (30 Days)
- RDI 27.9K
- FGEN 60.6K
- Earning Date
- RDI 08-13-2025
- FGEN 08-05-2025
- Dividend Yield
- RDI N/A
- FGEN N/A
- EPS Growth
- RDI N/A
- FGEN N/A
- EPS
- RDI N/A
- FGEN N/A
- Revenue
- RDI $205,644,000.00
- FGEN $6,996,000.00
- Revenue This Year
- RDI $7.47
- FGEN N/A
- Revenue Next Year
- RDI $13.22
- FGEN N/A
- P/E Ratio
- RDI N/A
- FGEN N/A
- Revenue Growth
- RDI N/A
- FGEN N/A
- 52 Week Low
- RDI $1.17
- FGEN $4.50
- 52 Week High
- RDI $1.89
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- RDI 45.69
- FGEN 37.76
- Support Level
- RDI $1.21
- FGEN $5.37
- Resistance Level
- RDI $1.37
- FGEN $5.73
- Average True Range (ATR)
- RDI 0.06
- FGEN 0.48
- MACD
- RDI -0.01
- FGEN 0.02
- Stochastic Oscillator
- RDI 42.05
- FGEN 28.78
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.